In contrast, expression of c-MYC, regulating the expression of MCL1 and eIF4E/BCLXL [133]; ribonuclease inhibitor (RNH1), impacting on the cellular redox status [134]; and inhibitor of growth protein 5 (ING5), regulating β-catenin and NF-κB and the Akt pathway [135], seems to mediate resistance to vorinostat, suggesting that their inhibition in combination with vorinostat could be a therapeutic solution for GC patients. The gene discussed is ING5; the disease is gastric cancer.